Castleman disease and associated autoimmune disease

Current Opinion in Rheumatology

Volumn 24, Issue 1, 2012, Pages 76-83

  Muskardina, Theresa W ^a,c   Peterson, Bruce A ^b   Molitor, Jerry A ^a  

^a Division of Rheumatic and Autoimmune Diseases   (United States)

^b Division of Hematology Oncology and Transplantation   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

B lymphocyte; Castleman disease; Innate immunity; Interferon; Interleukin 6; Plasmacytoid dendritic cell

Indexed keywords

B CELL ACTIVATING FACTOR; BORTEZOMIB; CD20 ANTIGEN; CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LENALIDOMIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SILTUXIMAB; THALIDOMIDE; TOCILIZUMAB; VASCULOTROPIN;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL TYPE; CONNECTIVE TISSUE DISEASE; DELAYED DIAGNOSIS; DISEASE ASSOCIATION; DRUG TARGETING; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PARANEOPLASTIC PEMPHIGUS; PATHOGENESIS; POEMS SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REMISSION; REVIEW; SKIN DEFECT; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; GIANT LYMPH NODE HYPERPLASIA; HUMANS;

EID: 82955233372     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834db525     Document Type: Review

References (50)

1. Castleman B, Inverson L, Menedex V. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956; 9:822-830.
2. Cronin D, Warnke R. Castleman disease: An update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009; 16:236-246.
3. Reddy D, Mitsuyasu R. HIV-associated multicentric Castleman disease. Curr Opin Oncol 2011; 23:475-481. A recent review of HIV-associated multicentric Castleman disease.
4. van Rhee F, Stone K, Szmania S, et al. Castleman disease in the 21st century: An update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010; 8:486-498. A recent comprehensive review of Castleman disease.
5. Parez N, Bader-Meunier B, Roy CC, et al. Paediatric Castleman disease: Report of seven cases and review of the literature. Eur J Pediatr 1999; 158:631-637. (Pubitemid 29331031)
6. Kim K, Cho C, Choi J. Pararenal retroperitoneal Castleman's disease mimicking systemic lupus erythematosus. Int J Rheum Dis 2010; 13:e20-e25. A report of a case of Castleman disease mimicking SLE.
7. Sari S, Okur A, Yesilkava E, et al. Localized abdominal Castleman disease masquerading as malabsorption syndrome. J Pediatr Hematol Oncol 2008; 30:618-620.
8. Venizelos I, Papthomas TG, Papathanasiou M, et al. Orbital involvement in Castleman disease. Surv Ophthalmol 2010; 55:247-255.
9. Kazakov DV, Fanburg-Smith JC, Suster S, et al. Castleman disease of the subcutis and underlying skeletal muscle: Report of 6 cases. Am J Surg Pathol 2004; 28:569-577. (Pubitemid 38579557)
10. Ko SF, Ng SH, Hsieh MJ, et al. Castleman disease of the pleura: Experience with eight surgically proven cases. Ann Thorac Surg 2003; 76:219-224.
11. Kanda J, Kawabata H, Yamaji Y, et al. Reversible cardiomyopathy associated with mulicentric Castleman disease: Successful treatment with tocilizumab, an antiinterleukin 6 receptor antibody. Int J Hematol 2007; 85:207-211. (Pubitemid 46686579)
12. De Marchi G, De Vita S, Fabris M, et al. Systemic connective tissue disease complicated by Castleman's disease: Report of a case and review of the literature. Haematologica 2004; 89:7-10.
13. Sato Y, Kojima M, Katsuyoshi T, et al. Multicentric Castleman's disease with abundant IgG4-positive cells: A clinical and pathological analysis of six cases. J Clin Pathol 2010; 63:1084-1089.
14. Casper C. The aetiology and management of Castleman disease at 50 years: Translating pathophysiology to patient care. Br J Haematol 2005; 129:3-17. (Pubitemid 40524047)
15. Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood 2011; 118:271-275.
16. Mimouni D, AnhaltGJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002; 147:725-732. (Pubitemid 35286158)
17. Dong Y, Na J, Lv J, et al. Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center. Leuk Lymph 2009; 50:1308-1317.
18. Nikokskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman's disease. Br J Dermatol 2003; 149:1143-1151. (Pubitemid 38058089)
19. Bhat L, Sams HH. Bullous pemphigoid associated with Castleman disease. Arch Dermatol 2001; 137:965-966. (Pubitemid 32641667)
20. Wang L, Bu D, Yang Y, Chen X, et al. Castleman's tumours and production of autoantibody in paraneoplastic pemphigus. Lancet 2004; 363:525-531. (Pubitemid 38229453)
21. Mascaro JM Jr, Ferrando J, Sole MT, et al. Paraneoplastic pemphigus: A case of long-term survival associated with systemic lupus erythematosus and polymyositis. Dermatology 1999; 199:63-66. (Pubitemid 29366792)
22. Kojima M, Nakamura S, Morishita Y, et al. Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: A clinicopathological and immunohistological study of 21 cases. Pathol Int 2000; 50:304-312. (Pubitemid 30441282)
23. Kojima M, Motoori T, Asano S, et al. Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients. Pathol Res Pract 2007; 203:423-431. (Pubitemid 46852314)
24. Kojima M, Motoori T, Nakamura S. Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients. Biomed Pharmacother 2006; 60:663-672. (Pubitemid 44822653)
25. Quinn JP, Gilligan OM, Horgan M. Evan's syndrome complicating multicentric Castleman's disease: Dramatic response to rituximab. Eur J Haematol 2004; 73:384-385. (Pubitemid 39349922)
26. Gakiopoulou H, Korkolopoulou P, Paraskevakou H, et al. Membranoproliferative glomerulonephritis in the setting of multicentric angiofollicular lymph node hyperplasia (Castleman's disease) complicated by Evan's syndrome. J Clin Pathol 2010; 63:552-554.
27. Bull T, Cool C, Serls A, et al. Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8. Eur Respir J 2003; 22:403-407. (Pubitemid 37098918)
28. Furuya Y, Satoh T, Masataka K. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheum 2010; 2010:1-8. A report of a case of mixed connective tissue disease with PAH and a course complicated by multicentric Castleman disease, successful treatment of the multicentric Castleman disease, and PAH with tocilizumab.
29. Karoui K, Vuiblet V, Dion D, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant 2011; 26:599-609. A review of renal biopsies of 19 patients with Castleman disease, revealing two main patterns of renal involvement in HIV-negative Castleman disease.
30. Dispenzieri A. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86:591-601. A comprehensive update on POEMS syndrome, including a description of a spectrum of disease among osteosclerotic myeloma, POEMS, and Castleman disease.
31. Shin DY, Jeon YK, Hong YS, et al. Clinical dissection of multicentric Castleman disease. Leuk Lymphoma 2011; 52:1517-1522. A retrospective study of 70 patients with Castleman disease at Seoul National University Hospital, with an investigation of prognostic factors.
32. Kulkarni GB, Mahadevan A, Taly AB, et al. Clinicopathological profile of polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome. J Clin Neurosci 2011; 18:356-360. A retrospective study of the clinical, electrophysiological, and pathological profile of 29 patients with POEMS.
33. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004; 16:801-807. (Pubitemid 39423672)
34. Laurent C, Meggetto F, Brousset P. Human herpesvirus 8 infections in patients with immunodeficiencies. Hum Pathol 2008; 39:983-993. (Pubitemid 351833114)
35. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989; 74:1360-1367. (Pubitemid 19227448)
36. Hirano T. Interleukin 6 in autoimmune and inflammatory diseases: A personal memoir. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86:717-730. Discussion of the research that led to the identification and characterization of IL-6 and the roles that IL-6 has on autoimmune and inflammatory diseases.
37. Brandt SJ, Bodine DM, Dunbar CE, et al. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990; 86:592-599. (Pubitemid 20271895)
38. Song SJ, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010; 116:3627-3634. A study investigating the roles of hepcidin and IL-6 in anemia and the long-term effects of tocilizumab in multicentric Castleman disease patients.
39. Dham A, Peterson BA. Castleman disease. Curr Opin Hematol 2007; 14:354-359. (Pubitemid 46842810)
40. Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92:670-676. (Pubitemid 32735205)
41. Tal Y, Haber G, Cohen MJ, et al. Autologous stem cell transplantaton in a rare multicentric Castleman disease of the plasma cell variant. Int J Hematol 2011; 93:677-680.
42. Ogita M, Hoshino J, Sogawa Y, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol 2007; 68:171-176. (Pubitemid 47377340)
43. Ocio EM, Sanchez-Guijo FM, Diez-Campelo, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol 2005; 78:302-305. (Pubitemid 40471124)
44. Mian H, Leber B. Mixed variant multicentric Castleman disease treated with rituximab: Case report. J Pediatr Hematol Oncol 2011; 32:622. A case report of pediatric response to rituximab in mixed multicentric Castleman disease.
45. Nishimoto N, Kishimoto T. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004; 4:386-391. (Pubitemid 38987066)
46. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized antiinterleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106:2627-2632. (Pubitemid 41510733)
47. Nishimoto N, Honda O, Sumikawa H, et al. A long-term (5-year) sustained efficacy of tocilizumab for multicentric Castleman's disease and the effect on pulmonary complications. Blood 2007; 110 (11 Pt 1): 646.
48. Centocor Inc. A study to evaluate the safety of long-term treatment with siltuximab in patients with multicentric Castleman's disease. In: Clinical Trials.gov [Internet, NLM Identifier: NCT01400503]. Bethesda, Maryland: National Library of Medicine (US); 2000. http://clinicaltrials.gov/ct2/show/ NCT01400503. [Accessed 4 August 2011]
49. Sobas MA, Vence NA, Arias JD, et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCDPOEMS variant). Ann Hematol 2010; 89:217-219.
50. Galeotti C, Tran T, Franchi-Abella S, et al. IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease. J Pediatr Hematol Oncol 2008; 30:920-924.